Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 131 | 47% |
| 2020 | 1 | 149 | 49% |
| 2021 | 3 | 220 | 51% |
| 2022 | 3 | 209 | 53% |
| 2023 | 3 | 219 | 56% |
| 2024 | 3 | 212 | 58% |
| 2025 from claims | – | 389 314–456 | 59% |
| 2026 forecast | – | 427 334–536 | 59% |
| 2027 forecast | – | 463 344–613 | 59% |
| 2028 forecast | – | 503 356–694 | 60% |
| 2029 forecast | – | 546 371–782 | 60% |
| 2030 forecast | – | 592 388–878 | 61% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Pennsylvania; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 51% inpatient hospital, 33% hospital outpatient, 16% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 0 | 175+8.8%/yr | +8.8%/yr | 0.1 | 0% | 450 in 2030+17%/yr |
| New Jersey | 3 | 157+9.2%/yr | +9.2%/yr | 0.1 | 100% | 260 in 2030+9.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 95 | 4,474−6.6%/yr | −6.6%/yr | 3.21.2× | 2% | 4,650 in 2030+0.6%/yr |
| Lumbar fusion | 89 | 3,644−1.8%/yr | −1.8%/yr | 2.61.4× | 3% | 3,820 in 2030+0.8%/yr |
| Cervical fusion & disc arthroplasty | 23 | 1,803−4.6%/yr | −4.6%/yr | 1.31.3× | 0% | 1,920 in 2030+1%/yr |
| Kyphoplasty & vertebroplasty | 13 | 1,396−2.9%/yr | −2.9%/yr | 1.01.3× | 12% | 1,330 in 2030−0.7%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
SI-BONE leads with 96% of company spending on these surgeons in 2025, +31 pts on 2024.
In 2025, 4 companies reported engagement with Pennsylvania’s surgeons worth $190K in consulting, speaking, meals and travel tied to these products, about $63K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.